Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 175

1.

Cytokinin treatment modifies litchi fruit pericarp anatomy leading to reduced susceptibility to post-harvest pericarp browning.

Fahima A, Levinkron S, Maytal Y, Hugger A, Lax I, Huang X, Eyal Y, Lichter A, Goren M, Stern RA, Harpaz-Saad S.

Plant Sci. 2019 Jun;283:41-50. doi: 10.1016/j.plantsci.2019.02.006. Epub 2019 Feb 13.

PMID:
31128712
2.

Radiation-induced brachial plexus toxicity after SBRT of apically located lung lesions.

Lindberg K, Grozman V, Lindberg S, Onjukka E, Lax I, Lewensohn R, Wersäll P.

Acta Oncol. 2019 Aug;58(8):1178-1186. doi: 10.1080/0284186X.2019.1601255. Epub 2019 May 8.

PMID:
31066326
3.

Structures of ligand-occupied β-Klotho complexes reveal a molecular mechanism underlying endocrine FGF specificity and activity.

Kuzina ES, Ung PM, Mohanty J, Tome F, Choi J, Pardon E, Steyaert J, Lax I, Schlessinger A, Schlessinger J, Lee S.

Proc Natl Acad Sci U S A. 2019 Apr 16;116(16):7819-7824. doi: 10.1073/pnas.1822055116. Epub 2019 Apr 3.

4.

Identification of a biologically active fragment of ALK and LTK-Ligand 2 (augmentor-α).

Reshetnyak AV, Mohanty J, Tomé F, Puleo DE, Plotnikov AN, Ahmed M, Kaur N, Poliakov A, Cinnaiyan AM, Lax I, Schlessinger J.

Proc Natl Acad Sci U S A. 2018 Aug 14;115(33):8340-8345. doi: 10.1073/pnas.1807881115. Epub 2018 Jul 30.

5.

Structures of β-klotho reveal a 'zip code'-like mechanism for endocrine FGF signalling.

Lee S, Choi J, Mohanty J, Sousa LP, Tome F, Pardon E, Steyaert J, Lemmon MA, Lax I, Schlessinger J.

Nature. 2018 Jan 25;553(7689):501-505. doi: 10.1038/nature25010. Epub 2018 Jan 17.

6.

Accuracy of the dose-shift approximation in estimating the delivered dose in SBRT of lung tumors considering setup errors and breathing motions.

Karlsson K, Lax I, Lindbäck E, Poludniowski G.

Acta Oncol. 2017 Sep;56(9):1189-1196. doi: 10.1080/0284186X.2017.1310395. Epub 2017 Apr 7.

PMID:
28388257
7.

Risk of Acute Testicular Failure After Preoperative Radiotherapy for Rectal Cancer: A Prospective Cohort Study.

Buchli C, Martling A, Abani MA, Frödin JE, Bottai M, Lax I, Arver S, Holm T.

Ann Surg. 2018 Feb;267(2):326-331. doi: 10.1097/SLA.0000000000002081.

PMID:
27849668
8.

SPACE - A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC.

Nyman J, Hallqvist A, Lund JÅ, Brustugun OT, Bergman B, Bergström P, Friesland S, Lewensohn R, Holmberg E, Lax I.

Radiother Oncol. 2016 Oct;121(1):1-8. doi: 10.1016/j.radonc.2016.08.015. Epub 2016 Sep 3.

PMID:
27600155
9.

Distinct cellular properties of oncogenic KIT receptor tyrosine kinase mutants enable alternative courses of cancer cell inhibition.

Shi X, Sousa LP, Mandel-Bausch EM, Tome F, Reshetnyak AV, Hadari Y, Schlessinger J, Lax I.

Proc Natl Acad Sci U S A. 2016 Aug 16;113(33):E4784-93. doi: 10.1073/pnas.1610179113. Epub 2016 Aug 1.

10.

Augmentor α and β (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand-receptor interactions.

Reshetnyak AV, Murray PB, Shi X, Mo ES, Mohanty J, Tome F, Bai H, Gunel M, Lax I, Schlessinger J.

Proc Natl Acad Sci U S A. 2015 Dec 29;112(52):15862-7. doi: 10.1073/pnas.1520099112. Epub 2015 Nov 16.

11.

Developmental and gender influences on executive function following concussion in youth hockey players.

Lax ID, Paniccia M, Agnihotri S, Reed N, Garmaise E, Azadbakhsh M, Ng J, Monette G, Wiseman-Hakes C, Taha T, Keightley M.

Brain Inj. 2015;29(12):1409-19. doi: 10.3109/02699052.2015.1043344. Epub 2015 Sep 11.

PMID:
26362811
12.

Assessment of testicular dose during preoperative radiotherapy for rectal cancer.

Buchli C, Al Abani M, Ahlberg M, Holm T, Fokstuen T, Bottai M, Frödin JE, Lax I, Martling A.

Acta Oncol. 2016;55(4):496-501. doi: 10.3109/0284186X.2015.1073349. Epub 2015 Sep 11.

PMID:
26362484
13.

Long-term results of a prospective phase II trial of medically inoperable stage I NSCLC treated with SBRT - the Nordic experience.

Lindberg K, Nyman J, Riesenfeld Källskog V, Hoyer M, Lund JÅ, Lax I, Wersäll P, Karlsson K, Friesland S, Lewensohn R.

Acta Oncol. 2015;54(8):1096-104. doi: 10.3109/0284186X.2015.1020966. Epub 2015 Mar 27.

PMID:
25813471
14.

Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK.

Murray PB, Lax I, Reshetnyak A, Ligon GF, Lillquist JS, Natoli EJ Jr, Shi X, Folta-Stogniew E, Gunel M, Alvarado D, Schlessinger J.

Sci Signal. 2015 Jan 20;8(360):ra6. doi: 10.1126/scisignal.2005916.

PMID:
25605972
15.

The strength and cooperativity of KIT ectodomain contacts determine normal ligand-dependent stimulation or oncogenic activation in cancer.

Reshetnyak AV, Opatowsky Y, Boggon TJ, Folta-Stogniew E, Tome F, Lax I, Schlessinger J.

Mol Cell. 2015 Jan 8;57(1):191-201. doi: 10.1016/j.molcel.2014.11.021. Epub 2014 Dec 24.

16.

Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities.

Lew ED, Oh J, Burrola PG, Lax I, Zagórska A, Través PG, Schlessinger J, Lemke G.

Elife. 2014 Sep 29;3. doi: 10.7554/eLife.03385.

17.

Treatment fractionation for stereotactic radiotherapy of lung tumours: a modelling study of the influence of chronic and acute hypoxia on tumour control probability.

Lindblom E, Antonovic L, Dasu A, Lax I, Wersäll P, Toma-Dasu I.

Radiat Oncol. 2014 Jun 30;9:149. doi: 10.1186/1748-717X-9-149.

18.

Survival and tumour control probability in tumours with heterogeneous oxygenation: a comparison between the linear-quadratic and the universal survival curve models for high doses.

Lindblom E, Dasu A, Lax I, Toma-Dasu I.

Acta Oncol. 2014 Aug;53(8):1035-40. doi: 10.3109/0284186X.2014.925582. Epub 2014 Jun 24.

PMID:
24957551
19.

The docking protein FRS2α is a critical regulator of VEGF receptors signaling.

Chen PY, Qin L, Zhuang ZW, Tellides G, Lax I, Schlessinger J, Simons M.

Proc Natl Acad Sci U S A. 2014 Apr 15;111(15):5514-9. doi: 10.1073/pnas.1404545111. Epub 2014 Apr 2.

20.

Structure, domain organization, and different conformational states of stem cell factor-induced intact KIT dimers.

Opatowsky Y, Lax I, Tomé F, Bleichert F, Unger VM, Schlessinger J.

Proc Natl Acad Sci U S A. 2014 Feb 4;111(5):1772-7. doi: 10.1073/pnas.1323254111. Epub 2014 Jan 21.

21.

Structural basis for KIT receptor tyrosine kinase inhibition by antibodies targeting the D4 membrane-proximal region.

Reshetnyak AV, Nelson B, Shi X, Boggon TJ, Pavlenco A, Mandel-Bausch EM, Tome F, Suzuki Y, Sidhu SS, Lax I, Schlessinger J.

Proc Natl Acad Sci U S A. 2013 Oct 29;110(44):17832-7. doi: 10.1073/pnas.1317118110. Epub 2013 Oct 14.

22.

Retrospective cohort study of bronchial doses and radiation-induced atelectasis after stereotactic body radiation therapy of lung tumors located close to the bronchial tree.

Karlsson K, Nyman J, Baumann P, Wersäll P, Drugge N, Gagliardi G, Johansson KA, Persson JO, Rutkowska E, Tullgren O, Lax I.

Int J Radiat Oncol Biol Phys. 2013 Nov 1;87(3):590-5. doi: 10.1016/j.ijrobp.2013.06.2055.

PMID:
24074933
23.

Alterations in frontostriatal pathways in children born very preterm.

Duerden EG, Card D, Lax ID, Donner EJ, Taylor MJ.

Dev Med Child Neurol. 2013 Oct;55(10):952-8. doi: 10.1111/dmcn.12198. Epub 2013 Jul 16.

24.

The impact of fractionation in SBRT: analysis with the linear quadratic model and the universal survival curve model.

Wennberg B, Lax I.

Acta Oncol. 2013 Jun;52(5):902-9. doi: 10.3109/0284186X.2012.728292. Epub 2013 Jan 17.

PMID:
23327339
25.

A retrospective study of SBRT of metastases in patients with primary sarcoma.

Stragliotto CL, Karlsson K, Lax I, Rutkowska E, Bergh J, Strander H, Blomgren H, Friesland S.

Med Oncol. 2012 Dec;29(5):3431-9. doi: 10.1007/s12032-012-0256-2. Epub 2012 Jul 20.

26.

Neuroanatomical consequences of very preterm birth in middle childhood.

Lax ID, Duerden EG, Lin SY, Mallar Chakravarty M, Donner EJ, Lerch JP, Taylor MJ.

Brain Struct Funct. 2013 Mar;218(2):575-85. doi: 10.1007/s00429-012-0417-2. Epub 2012 May 11.

PMID:
22572806
27.

Suppression of EGFR endocytosis by dynamin depletion reveals that EGFR signaling occurs primarily at the plasma membrane.

Sousa LP, Lax I, Shen H, Ferguson SM, De Camilli P, Schlessinger J.

Proc Natl Acad Sci U S A. 2012 Mar 20;109(12):4419-24. doi: 10.1073/pnas.1200164109. Epub 2012 Feb 27.

28.

Toxicity after reirradiation of pulmonary tumours with stereotactic body radiotherapy.

Peulen H, Karlsson K, Lindberg K, Tullgren O, Baumann P, Lax I, Lewensohn R, Wersäll P.

Radiother Oncol. 2011 Nov;101(2):260-6. doi: 10.1016/j.radonc.2011.09.012. Epub 2011 Nov 5.

PMID:
22056534
29.

Stereotactic radiotherapy of primary lung cancer and other targets: results of consultant meeting of the International Atomic Energy Agency.

Nagata Y, Wulf J, Lax I, Timmerman R, Zimmermann F, Stojkovski I, Jeremic B.

Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):660-9. doi: 10.1016/j.ijrobp.2010.10.004. Review.

PMID:
21281896
30.

NTCP modelling of lung toxicity after SBRT comparing the universal survival curve and the linear quadratic model for fractionation correction.

Wennberg BM, Baumann P, Gagliardi G, Nyman J, Drugge N, Hoyer M, Traberg A, Nilsson K, Morhed E, Ekberg L, Wittgren L, Lund JÅ, Levin N, Sederholm C, Lewensohn R, Lax I.

Acta Oncol. 2011 May;50(4):518-27. doi: 10.3109/0284186X.2010.543695. Epub 2011 Jan 4.

PMID:
21198416
31.

FRS2α regulates Erk levels to control a self-renewal target Hes1 and proliferation of FGF-responsive neural stem/progenitor cells.

Sato T, Shimazaki T, Naka H, Fukami S, Satoh Y, Okano H, Lax I, Schlessinger J, Gotoh N.

Stem Cells. 2010 Sep;28(9):1661-73. doi: 10.1002/stem.488.

32.

Undetectable late hepatic sequelae after hypofractionated stereotactic radiotherapy for liver tumors.

Gunvén P, Jonas E, Blomgren H, Rutkowska E, Karlsson K, Lax I, Levitt S.

Med Oncol. 2011 Dec;28(4):958-65. doi: 10.1007/s12032-010-9567-3. Epub 2010 May 19.

PMID:
20490719
33.

Asymmetric receptor contact is required for tyrosine autophosphorylation of fibroblast growth factor receptor in living cells.

Bae JH, Boggon TJ, Tomé F, Mandiyan V, Lax I, Schlessinger J.

Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):2866-71. doi: 10.1073/pnas.0914157107. Epub 2010 Jan 26.

34.

Stereotactic body radiation therapy for early non-small cell lung cancer.

Zimmermann F, Wulf J, Lax I, Nagata Y, Timmerman RD, Stojkovski I, Jeremic B.

Front Radiat Ther Oncol. 2010;42:94-114. doi: 10.1159/000262465. Epub 2009 Nov 24. Review.

PMID:
19955796
35.

The selectivity of receptor tyrosine kinase signaling is controlled by a secondary SH2 domain binding site.

Bae JH, Lew ED, Yuzawa S, Tomé F, Lax I, Schlessinger J.

Cell. 2009 Aug 7;138(3):514-24. doi: 10.1016/j.cell.2009.05.028.

36.

Surgical displacement of risk organs to improve stereotactic radiotherapy for liver tumors.

Gunvén P, Jonas E, Wersäll P, Lax I.

J Surg Oncol. 2009 Nov 1;100(6):515-7. doi: 10.1002/jso.21366.

PMID:
19653246
37.

Surface binding inhibitors of the SCF-KIT protein-protein interaction.

Margulies D, Opatowsky Y, Fletcher S, Saraogi I, Tsou LK, Saha S, Lax I, Schlessinger J, Hamilton AD.

Chembiochem. 2009 Aug 17;10(12):1955-8. doi: 10.1002/cbic.200900079. No abstract available.

38.

AAA and PBC calculation accuracy in the surface build-up region in tangential beam treatments. Phantom and breast case study with the Monte Carlo code PENELOPE.

Panettieri V, Barsoum P, Westermark M, Brualla L, Lax I.

Radiother Oncol. 2009 Oct;93(1):94-101. doi: 10.1016/j.radonc.2009.05.010. Epub 2009 Jun 21.

PMID:
19541380
39.

Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy.

Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I, Drugge N, Ekberg L, Friesland S, Johansson KA, Lund JA, Morhed E, Nilsson K, Levin N, Paludan M, Sederholm C, Traberg A, Wittgren L, Lewensohn R.

J Clin Oncol. 2009 Jul 10;27(20):3290-6. doi: 10.1200/JCO.2008.21.5681. Epub 2009 May 4.

PMID:
19414667
40.

Curative stereotactic body radiotherapy for liver malignancy.

Gunvén P, Blomgren H, Lax I, Levitt SH.

Med Oncol. 2009;26(3):327-34. doi: 10.1007/s12032-008-9125-4. Epub 2008 Nov 14.

PMID:
19009370
41.

Exploring the healthcare journey of patients with rheumatoid arthritis: a mapping project - implications for practice.

Oliver S, Bosworth A, Airoldi M, Bunyan H, Callum A, Dixon J, Home D, Lax I, O'Brien A, Redmond A, Ryan S, Scott DG, Steuer A, Tanner L.

Musculoskeletal Care. 2008 Dec;6(4):247-66. doi: 10.1002/msc.139.

PMID:
18785194
42.

Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study.

Baumann P, Nyman J, Hoyer M, Gagliardi G, Lax I, Wennberg B, Drugge N, Ekberg L, Friesland S, Johansson KA, Lund JS, Morhed E, Nilsson K, Levin N, Paludan M, Sederholm C, Traberg A, Wittgren L, Lewensohn R.

Radiother Oncol. 2008 Sep;88(3):359-67. doi: 10.1016/j.radonc.2008.07.019. Epub 2008 Sep 1.

PMID:
18768228
43.

Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney.

Svedman C, Karlsson K, Rutkowska E, Sandström P, Blomgren H, Lax I, Wersäll P.

Acta Oncol. 2008;47(8):1578-83. doi: 10.1080/02841860802123196.

PMID:
18607859
44.

Is repeated radiosurgery an alternative to staged radiosurgery for very large brain arteriovenous malformations?

Karlsson B, Jokura H, Yamamoto M, Söderman M, Lax I.

J Neurosurg. 2007 Oct;107(4):740-4.

PMID:
17937217
45.

Lacrimo-auriculo-dento-digital syndrome is caused by reduced activity of the fibroblast growth factor 10 (FGF10)-FGF receptor 2 signaling pathway.

Shams I, Rohmann E, Eswarakumar VP, Lew ED, Yuzawa S, Wollnik B, Schlessinger J, Lax I.

Mol Cell Biol. 2007 Oct;27(19):6903-12. Epub 2007 Aug 6.

46.

SBRT of lung tumours: Monte Carlo simulation with PENELOPE of dose distributions including respiratory motion and comparison with different treatment planning systems.

Panettieri V, Wennberg B, Gagliardi G, Duch MA, Ginjaume M, Lax I.

Phys Med Biol. 2007 Jul 21;52(14):4265-81. Epub 2007 Jun 20.

PMID:
17664607
47.

Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor.

Yuzawa S, Opatowsky Y, Zhang Z, Mandiyan V, Lax I, Schlessinger J.

Cell. 2007 Jul 27;130(2):323-34.

48.

Calculation of isoeffective doses and the alpha/beta value by comparing results following radiosurgery and radiotherapy for arteriovenous malformations of the brain.

Karlsson B, Lax I, Yamamoto M, Söderman M, Jokura H, Rosen C, Bailes J.

J Neurosurg. 2006 Dec;105 Suppl:183-9. Review.

PMID:
18503354
49.

Attenuation of signaling pathways stimulated by pathologically activated FGF-receptor 2 mutants prevents craniosynostosis.

Eswarakumar VP, Ozcan F, Lew ED, Bae JH, Tomé F, Booth CJ, Adams DJ, Lax I, Schlessinger J.

Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18603-8. Epub 2006 Nov 28.

50.

Dose distributions in SBRT of lung tumors: Comparison between two different treatment planning algorithms and Monte-Carlo simulation including breathing motions.

Lax I, Panettieri V, Wennberg B, Amor Duch M, Näslund I, Baumann P, Gagliardi G.

Acta Oncol. 2006;45(7):978-88.

PMID:
16982567

Supplemental Content

Support Center